Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
Information source: Galderma Laboratories, L.P.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Erythema; Rosacea
Intervention: CD07805/47 gel 0.5%/CD07805/47 Vehicle (Drug); azelaic acid gel 15% (Drug)
Phase: Phase 3
Sponsored by: Galderma Laboratories, L.P.
Official(s) and/or principal investigator(s):
Ronald W. Gottschalk, MD, Study Director, Affiliation: Galderma Laboratories, L.P.
The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel
0. 5% applied topically once daily versus azelaic acid gel 15% applied topically twice daily
in subjects with moderate to severe facial erythema of rosacea.
Official title: A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Composite Success
Secondary outcome: Onset of Action
Adult subjects with moderate to severe facial erythema of rosacea who meet
inclusion/exclusion criteria will be randomized at Baseline/Visit 1 in a 1: 1 ratio to
receive either CD07805/47 gel 0. 5% once daily or azelaic acid gel 15% twice daily for 15
days. Following an appropriate washout period, subjects will then switch treatments and use
the second investigational product as instructed for 15 days (according to the subject's
randomization scheme). Subjects will re-qualify based upon inclusion/exclusion prior to
Period 2 treatment.
Minimum age: 18 Years.
Maximum age: N/A.
1. Subject is male or female aged 18 years or older.
2. Subject has a clinical diagnosis of facial rosacea.
3. Subject has a clinician's assessment score of moderate to severe erythema prior to
4. Subject has a self assessment score of moderate to severe redness prior to
5. Subjects with none to mild facial inflammatory lesions of rosacea prior to
1. Female subjects who are pregnant, nursing or planning a pregnancy during the study.
2. Subjects with a condition or who are in a situation, which in the Investigator's
opinion may put a subject at risk, may confound study results, or may interfere with
a subject's participation in the study.
3. Subjects with conditions causing facial erythema which would confound the assessment
4. Subjects who are taking or have recently taken medications known to have interactions
with α2-adrenergic agonists.
5. Subjects with known allergies or sensitivities to one of the components of the
Locations and Contacts
Hudson Dermatology, Evansville, Indiana 47714, United States
Dermatology Specialists Research, LLC, Louisville, Kentucky 40202, United States
DermResearch, Inc, Austin, Texas 78759, United States
The Education & Research Foundation, Inc., Lynchburg, Virginia 24501, United States
Starting date: September 2012
Last updated: July 8, 2014